PROKPROKIDNEY CORP.

0.2×

Top 72% of the Russell 3000. How it works

Clinical-stage biotech developing autologous kidney cell therapy (rilparencel) for advanced CKD with diabetes.

Recurring revenue0/10
AI-rollup fit0/10
Services share1/10
Labor intensity2/10
Work AI could do1/10
Fragmented market0/10

Deal filings

Filed	Form	Acquirer	Price	Premium
Jun 10, 2022	DEFM14A	—	—	—
Feb 14, 2022	PREM14A	—	—	—

Key numbers

Revenue: —
Operating margin: —
EBITDA: —
Net debt / EBITDA: —

Financials

No XBRL financials yet.